STOCKS NEWS Reuters Results diary
Europe Real-time Equity News

14:15GMT 07Nov2008-Meldex falls on financing concerns

Shares in speciality drug company Meldex tumble 14 percent to 10.5 pence on financing concerns after it announces two directors have sold shares at 7.5 pence each to raise cash which is being lent back to the company as a bridge loan.
"This is clearly highlighting a concern that there are financing issues at the company, it's an unusual thing to do," says Robin Davison, analyst at Edison.
The company has also signed a term sheet with an investment company to inject up to 3 million pounds ($4.71 million) by way of a debt facility to the company.
For more double click on

Reuters Messaging rm://ben.deighton.reuters.com@reuters.net
12:03GMT 07Nov2008-Findel up on rate cut boost

Shares in Findel soar 21 percent to 114.75 pence as the market continues to respond to Thursday's 150 basis point interest rate cut, which analysts feel will benefit highly leveraged retailers.
The shopping catalogue and educational supplies company has net debt of around 400 million pounds.

"Lower interest rates will take some pressure off the highly leveraged companies in the sector, including Findel...(but) retailers will still be impacted by the stronger dollar and the likelihood of greater discount activity," says Seymour Pierce analyst Freddie George. Reuters messaging rm://rhysl.jones.reuters.com@reuters.net
11:38GMT 07Nov2008-Bayer up as Xarelto drug sales seen strong

Shares in Bayer AG rise 3.5 percent, helped by a Deutsche Bank report that says the drugmaker could see strong sales after its anticoagulant drug Xarelto showed promising results in a mid-stage clinical trial.
"Bayer's stock is seeing gains on the Deutsche Bank report," says a Frankfurt-based trader.
"We expect Xarelto to deliver better data both on the safety as well as the efficacy side, yet again demonstrating Xarelto's potential to dominate the anticoagulation space," writes Deutsche analyst Tim Jones in a note to clients.
Bayer estimates eventual global peak sales of Xarelto, which is already approved in Europe for preventing blood clots after orthopaedic surgery, could reach 2 billion euros ($2.6 billion) a year for all indications.
Deutsche Bank analysts, however, see the drug with the potential to earn at least 3 billion euros from just one of its applications -- to treat acute coronary syndrome.
For more double click on

Reuters Messaging rm://tyler.sitte.thomsonreuters.com@thomsonreuters.net

COPYRIGHT

Copyright Thomson Reuters 2008. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.